<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787562</url>
  </required_header>
  <id_info>
    <org_study_id>XNW4107-003</org_study_id>
    <nct_id>NCT04787562</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function</brief_title>
  <official_title>A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF XNW4107, IMIPENEM AND CILASTATIN ADMINISTERED CONCURRENTLY AS INTRAVENOUS INFUSION TO SUBJECTS WITH VARIOUS DEGREES OF RENAL FUNCTION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovent Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovent Pty Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label study to assess the PK, safety and tolerability of XNW4107,&#xD;
      imipenem and cilastatin administered by 60-minute (60-min) IV infusion to adults with various&#xD;
      degrees of renal insufficiency as compared to subjects with normal renal function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total body clearance (CL) of XNW4107, imipenem and cilastatin in subjects with various of Renal function.</measure>
    <time_frame>From baseline to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent steady-state volume of distribution (Vss) of XNW4107, imipenem and cilastatin in subjects with various of Renal function.</measure>
    <time_frame>From baseline to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve from time zero to infinity (AUC0-∞)of XNW4107, imipenem and cilastatin in subjects with various of Renal function.</measure>
    <time_frame>From baseline to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of XNW4107, imipenem and cilastatin in subjects with various of Renal function.</measure>
    <time_frame>From baseline to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the maximum plasma concentration (Tmax) of XNW4107, imipenem and cilastatin in subjects with various of Renal function.</measure>
    <time_frame>From baseline to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The terminal elimination half-life (t1/2) of XNW4107, imipenem and cilastatin in subjects with various of Renal function.</measure>
    <time_frame>From baseline to 48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event (include SAEs) will be assessed and categorized.</measure>
    <time_frame>From baseline up to 10 days post-dose</time_frame>
    <description>Safety and tolerability up to the last study visit as assessed by the percentage of treatment-emergent AEs [including serious adverse events (SAEs)] categorized by severity, relationship to study drug, system organ class (SOC), AE preferred term (PT), along with percentage of clinically significant changes from baseline in clinical laboratory values, physical examination, vital signs, and ECG parameters.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Cohort 1: normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with an eGFR ≥ 90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Mild renal insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with an eGFR 60 to &lt;90 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Moderate renal insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with an eGFR 30 to &lt;60 mL/min/1.73m2 receive a single dose of XNW4107 250mg IV co-administered with imipenem 500mg /cilastatin 500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Severe renal insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with an eGFR 15 to &lt;30 mL/min/1.73m2 receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: End-stage renal disease (ESRD) receiving hemodialysis (HD) therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with ESRD receiving HD therapy at least 3 times a week for at least 3 months prior to Screening visit receive a single dose of XNW4107 100mg IV co-administered with imipenem 200mg /cilastatin 200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XNW4107, Imipenem/Cilastatin</intervention_name>
    <description>Drug: XNW4107 250mg IV over 60 minutes as a single dose&#xD;
Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose</description>
    <arm_group_label>Cohort 1: normal renal function</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XNW4107, Imipenem/Cilastatin</intervention_name>
    <description>Drug: XNW4107 250mg IV over 60 minutes as a single dose&#xD;
Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose</description>
    <arm_group_label>Cohort 2: Mild renal insufficiency</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XNW4107, Imipenem/Cilastatin</intervention_name>
    <description>Drug: XNW4107 250mg IV over 60 minutes as a single dose&#xD;
Drug: Imipenem/Cilastatin 500mg/500mg IV over 60 minutes as a single dose</description>
    <arm_group_label>Cohort 3: Moderate renal insufficiency</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XNW4107, Imipenem/Cilastatin</intervention_name>
    <description>Drug: XNW4107 100mg IV over 60 minutes as a single dose&#xD;
Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose</description>
    <arm_group_label>Cohort 4: Severe renal insufficiency</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XNW4107, Imipenem/Cilastatin</intervention_name>
    <description>Drug: XNW4107 100mg IV over 60 minutes as a single dose&#xD;
Drug: Imipenem/Cilastatin 200mg/200mg IV over 60 minutes as a single dose</description>
    <arm_group_label>Cohort 5: End-stage renal disease (ESRD) receiving hemodialysis (HD) therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Adult males or females, 18 years of age or older.&#xD;
&#xD;
             2. BMI ≥ 18.5 and ≤ 39.9 (kg/m²) and weight between 50.0 and 130.0 kg (inclusive).&#xD;
&#xD;
             3. Medically healthy (Cohort 1 only) or medically stable without clinically&#xD;
             significant acute or chronic illness (Cohorts 2-5) that may impact the assessment of&#xD;
             PK and safety.&#xD;
&#xD;
             4. Normal renal function with eGFR ≥90 mL/min/1.73m² (Cohort 1), or renal&#xD;
             insufficiency with eGFR 60 to &lt;90 mL/min/1.73m² (Cohort 2), 30 to &lt;60 mL/min/1.73m²&#xD;
             (Cohort 3), or 15 to &lt;30 mL/min/1.73m² (Cohort 4), ESRD receiving HDs at least 3 times&#xD;
             per week for at least 3 months at Screening (Cohort 5)&#xD;
&#xD;
             5. Participants of reproductive potential (male or female) must be willing to use&#xD;
             contraception.&#xD;
&#xD;
             6. Ability and willingness to abstain from alcohol, caffeine, xanthine-containing&#xD;
             beverages or food or product containing any of these from 48 hours prior to study drug&#xD;
             administration until discharge from the clinical unit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Any clinically significant medical history or abnormal findings upon physical&#xD;
             examination, or clinical laboratory tests.&#xD;
&#xD;
             2. Electrocardiogram (ECG) with QTcF interval duration equal or greater than 500 msec&#xD;
             obtained at Screening or Check-In.&#xD;
&#xD;
             3. Results for alanine aminotransferase (ALT), aspartate aminotransferase (AST) and&#xD;
             bilirubin greater than 1.5 × the upper limit of normal (ULN) for the reference&#xD;
             laboratory.&#xD;
&#xD;
             4. History of chronic liver disease, cirrhosis, or biliary disease.&#xD;
&#xD;
             5. History or presence of CNS disorders, seizures, or other CNS adverse reactions such&#xD;
             as confusional states and myoclonic activity.&#xD;
&#xD;
             6. Positive testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
             at Screening.&#xD;
&#xD;
             7. Close contact with anyone who tested positive for SARS-CoV-2 infection, or presence&#xD;
             of symptoms associated with SARS-CoV-2 infection at Screening or Check-in, or within&#xD;
             14 days prior to Screening.&#xD;
&#xD;
             8. Recent history (within 6 months) of known or suspected Clostridium difficile&#xD;
             infection.&#xD;
&#xD;
             9. Positive testing for HIV Ab, HBsAg or HCV Ab.&#xD;
&#xD;
             10. Recent history of substance or alcohol abuse within the previous year, or habitual&#xD;
             use of tobacco or nicotine products or smoking within 3 months prior to Screening.&#xD;
&#xD;
             11. Positive drug screen and alcohol testing at Screening or Check-in.&#xD;
&#xD;
             12. For subjects with normal renal function (Cohort 1), the use of any&#xD;
             over-the-counter (OTC) medications within 7 days prior to study drug administration or&#xD;
             use of prescription medications including nonsteroidal anti-inflammatory drugs, health&#xD;
             supplements, and herbal remedies taken within 13 days prior to study drug&#xD;
             administration.&#xD;
&#xD;
             13. For subjects with renal impairment (Cohorts 2-5), the use of prohibited&#xD;
             concomitant medication with the exception of those essential for the management of&#xD;
             renal impairment and other concomitant stable medical conditions as per the discretion&#xD;
             of the Investigator.&#xD;
&#xD;
             14. Use of probenecid or valproic acid within 30 days prior to study drug&#xD;
             administration.&#xD;
&#xD;
             15. Receipt of an investigational drug within 30 days or 5 half-lives prior to the&#xD;
             first administration of study drug, whichever is longer.&#xD;
&#xD;
             16. Known history of clinically significant hypersensitivity reaction or anaphylaxis&#xD;
             to any medication, or history of clinically significant hypersensitivity to the study&#xD;
             drug or any related drugs or to any of the excipients, or history of food intolerance.&#xD;
&#xD;
             17. Donation of blood or plasma within 30 days prior to dosing, or loss of whole blood&#xD;
             of more than 500 mL within 30 days prior to dosing, or receipt of a blood transfusion&#xD;
             within 1 year of study enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Clinical Pharmacology (DCP), University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard A. Preston, M.D.</last_name>
      <phone>305-243-6795</phone>
      <email>rpreston@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center (OCRC)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809-3017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas C. Marbury, M.D.</last_name>
      <phone>407-472-0227</phone>
      <email>tmarbury@ocrc.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

